Supplemental Table S6. Real-Time PCR and nCounter expression values of selected genes in MPM cell lines treated with guadecitabine vs untreated ones

	NY-ESO-1		MAGE-A1		CDH1		CDH2		IFN-γ		IFNGR		IL-1β		IL-6		IL-10	
	nCounter	qRT-PCR	nCounter	qRT-PCR	nCounter	qRT-PCR	nCounter	qRT-PCR	nCounter	qRT-PCR	nCounter	qRT-PCR	nCounter	qRT-PCR	nCounter	qRT-PCR	nCounter	qRT-PCR
Meso3 Untreated	1.1[a]	8.13E-05[b]	681.14	4.45E-02	11.78	2.10E-04	2843.92	6.05E-02	1.91	3.83E-07	636.15	7.36E-03	144.55	1.29E-03	111.64	4.08E-04	7.39	2.85E-05
Meso3 Guadecitabine 1 µM	479.75	5.30E-02	1022.06	1.36E-01	73.29	1.92E-03	1626.13	7.94E-02	1.12	2.07E-05	468.52	1.63E-02	167.61	3.07E-03	351.75	4.11E-03	1.12	1.26E-05
Meso2 Untreated	1	1.74E-05	196.64	1.53E-02	4.03	7.00E-05	4040.26	2.38E-01	1.00	7.67E-07	549.70	1.42E-02	133.95	3.56E-04	673.32	3.39E-03	2.46	1.11E-05
Meso2 Guadecitabine 1 µM	35.79	3.49E-03	281.70	3.03E-02	48.68	2.87E-03	2251.79	9.72E-02	2.63	1.20E-06	500.91	1.46E-02	243.94	1.69E-03	1676.14	1.07E-02	1.00	1.02E-04
Meso11 Untreated	1.45	1.26E-05	1.45	5.70E-06	12.06	8.48E-06	5633.46	1.31E-01	1.45	7.66E-07	1306.29	2.91E-02	2699.29	6.04E-02	17731.82	1.70E-01	1.45	1.45E-06
Meso11 Guadecitabine 1 µM	1.35	5.96E-04	41.61	3.25E-04	36.22	3.30E-04	4309.50	1.06E-01	1.00	3.55E-06	1823.72	3.72E-02	1153.74	2.08E-02	17819.53	1.29E-01	1.35	8.48E-06
Meso8 Untreated	1	9.80E-06	1.00	4.80E-06	9.10	6.24E-06	2166.34	5.84E-02	1.00	6.37E-07	890.06	1.88E-02	54.26	1.40E-03	4786.18	4.87E-02	1.00	5.10E-07
Meso8 Guadecitabine 1 µM	5.43	8.08E-04	58.22	1.19E-03	133.76	2.01E-03	1680.97	3.77E-02	1.00	1.83E-05	9.11	1.64E-02	37.29	9.24E-04	3822.48	2.44E-02	1.00	1.98E-05
Meso4 Untreated	1	2.18E-04	1.00	4.96E-05	3526.60	1.64E-01	732.23	6.22E-02	1.00	1.83E-06	611.75	3.67E-02	1.00	4.94E-04	1624.32	4.05E-02	1.00	7.95E-05
Meso4 Guadecitabine 1 µM	192.95	2.33E-02	90.08	3.51E-03	3864.86	1.04E-01	533.30	2.66E-02	1.00	4.79E-06	566.56	2.63E-02	1.00	1.73E-04	763.81	2.06E-02	1.00	3.80E-04
Meso13 Untreated	1	7.04E-06	11.78	5.29E-06	1089.07	1.62E-02	439.07	9.43E-03	1.00	1.70E-06	886.60	6.51E-03	1344.26	3.65E-04	10516.59	2.24E-04	1.00	0.00E+00
Meso13 Guadecitabine 1 µM	15.42	1.98E-03	26.63	5.58E-04	1206.74	1.87E-02	598.62	9.46E-03	1.50	4.93E-07	928.45	6.88E-03	1594.18	4.50E-04	7456.80	1.44E-03	1.50	5.92E-07
Meso5 Untreated	1.03	2.44E-04	9.04	7.90E-05	4658.08	2.22E-01	967.86	6.91E-02	5.19	7.73E-07	322.76	6.25E-02	23.33	2.09E-04	17.56	1.16E-02	2.71	7.00E-06
Meso5 Guadecitabine 1 µM	28.25	1.02E-02	56.54	5.56E-03	3275.11	1.92E-01	833.16	6.79E-02	1.25	1.03E-05	397.98	6.08E-02	21.65	1.23E-04	164.95	2.52E-02	1.25	1.53E-06
Meso7 Untreated	1	7.20E-05	34.80	2.77E-03	94.16	1.77E-03	978.61	3.28E-02	1.03	7.25E-07	1033.70	2.66E-02	1.00	6.00E-02	440.10	1.29E-01	1.03	9.87E-06
Meso7 Guadecitabine 1 µM	94.79	9.62E-03	37.81	3.13E-03	159.26	2.02E-03	857.92	1.76E-02	1.00	9.20E-07	764.30	1.79E-02	1.03	3.90E-02	789.92	6.17E-02	1.00	5.37E-06
Meso1 Untreated	1.04	1.14E-05	6.84	1.75E-05	11283.90	1.78E-01	1.04	3.30E-05	1.04	7.85E-06	542.76	7.67E-03	18.25	3.34E-04	159.22	1.63E-03	1.04	8.13E-06
Meso1 Guadecitabine 1 µM	113.92	8.10E-03	96.65	1.29E-03	7115.91	1.28E-01	1.08	1.88E-05	1.68	4.10E-06	721.52	1.26E-02	24.34	8.24E-04	281.20	2.86E-03	1.08	5.00E-06
Meso6 Untreated	1.19	2.10E-05	5.59	4.53E-05	5231.79	7.81E-02	1.19	2.22E-05	1.19	8.79E-07	1825.78	2.79E-02	40.09	6.65E-04	44.85	3.83E-04	1.19	1.54E-07
Meso6 Guadecitabine 1 µM	71.02	3.45E-03	78.72	6.31E-04	6696.13	1.11E-01	2.54	9.00E-05	1.00	4.49E-06	1534.71	2.52E-02	25.65	4.59E-04	620.54	5.26E-03	3.40	2.90E-07

[a] Values represent gene specific expression nCounter data (Log2 ratio)

[b] Data are reported as the number of immune molecules-specific mRNA normalized to the number of β-actin molecules, obtained by qRT-PCR analysis